Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Conditional restriction
WADA 2026: topical eye administration is excepted from S5. Other routes do not receive that exception. The future 2027 List retains it. [1] [2]
2026 and 2027 List, S5, printed p.12; introductory definitions p.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical and pharmacological context
US ophthalmic-suspension labeling describes a carbonic anhydrase inhibitor for elevated eye pressure in ocular hypertension or open-angle glaucoma. The drug can be systemically absorbed after eye administration. [3]
- The cited country-specific product information does not establish worldwide authorization or current supply.
Health concerns
Warnings include sulfonamide hypersensitivity and corneal edema in susceptible patients. The reviewed label does not recommend use in severe kidney impairment. [3]
- Selected warnings, not a complete contraindication or interaction list. Patient-label evidence does not establish athlete safety.
Combination eye drops
The eye-route exception does not clear an entire combination product. WADA separately restricts beta-blocker eye drops in particular sports. [4]
What remains uncertain
- Educational synthesis only; not individualized medical advice, a TUE decision or a sanction prediction.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Introduction p.3 · S5 p.12
- WADA 2027 Prohibited List, 4 November revision ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected · FUTURE 2027 SOURCE
Introduction p.3 · S5 p.12
- DailyMed brinzolamide ophthalmic suspension ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Indications; clinical pharmacology or SmPC sections 4.1 and 5.1 · Warnings, precautions and adverse reactions
- WADA Prohibited List and FAQs ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
FAQ: eye drops containing beta-blockers · FAQ: intravenous iron dextran · WADA mannitol FAQ; Bronchitol indication and bronchospasm warning
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.